Sanofi SA Company Profile (EPA:SAN)

About Sanofi SA (EPA:SAN)

Sanofi SA logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: EPA:SAN
  • CUSIP: N/A
  • Web: en.sanofi.com
Average Prices:
  • 50 Day Moving Avg: €26.11
  • 200 Day Moving Avg: €26.02
P/E:
  • Trailing P/E Ratio: 11.70
  • P/E Growth: 2.33
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 11.65%
 

Frequently Asked Questions for Sanofi SA (EPA:SAN)

What is Sanofi SA's stock symbol?

Sanofi SA trades on the EPA under the ticker symbol "SAN."

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

16 analysts have issued 12 month price targets for Sanofi SA's stock. Their predictions range from €75.00 to €100.00. On average, they expect Sanofi SA's stock price to reach €88.50 in the next twelve months. View Analyst Ratings for Sanofi SA.

Who are some of Sanofi SA's key competitors?

Who are Sanofi SA's key executives?

Sanofi SA's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee


MarketBeat Community Rating for Sanofi SA (EPA SAN)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  795
MarketBeat's community ratings are surveys of what our community members think about Sanofi SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi SA (EPA:SAN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: €88.50
Consensus Price Target History for Sanofi SA (EPA:SAN)
Price Target History for Sanofi SA (EPA:SAN)
Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetDetails
10/18/2017Deutsche Bank AGSet Price TargetBuy€96.00View Rating Details
10/17/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral€82.00View Rating Details
10/16/2017Jefferies Group LLCSet Price TargetNeutral€90.00View Rating Details
10/6/2017Citigroup Inc.Set Price TargetNeutral€88.00View Rating Details
10/6/2017Morgan StanleySet Price TargetBuy€92.00View Rating Details
9/14/2017J P Morgan Chase & CoSet Price TargetNeutral€85.00View Rating Details
9/12/2017HSBC Holdings plcSet Price TargetNeutral€81.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
9/7/2017Kepler Capital MarketsSet Price TargetBuy€90.00View Rating Details
7/31/2017Sanford C. BernsteinSet Price TargetNeutral€90.00View Rating Details
7/31/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
7/31/2017S&P GlobalSet Price TargetNeutral€90.00View Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
5/8/2017Barclays PLCSet Price TargetSell€75.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
12/6/2016S&P Global Inc.Set Price TargetNeutral€80.00View Rating Details
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sanofi SA (EPA:SAN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)
Source:
DateHeadline
americanbankingnews.com logoDeutsche Bank AG Reiterates "€96.00" Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - October 18 at 10:59 AM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 18 at 10:30 AM
reuters.com logoRegeneron-Sanofi throat infection drug succeeds key study - Reuters
www.reuters.com - October 17 at 3:35 PM
nytimes.com logoRegeneron-Sanofi Drug Succeeds Mid-Stage Study - New York Times
www.nytimes.com - October 17 at 3:35 PM
finance.yahoo.com logoRegeneron-Sanofi drug succeeds mid-stage study
finance.yahoo.com - October 17 at 3:35 PM
americanbankingnews.com logoSanofi SA (SAN) PT Set at €82.00 by Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 17 at 12:16 PM
reuters.com logoRegeneron-Sanofi food allergy drug succeeds mid-stage study - Reuters
www.reuters.com - October 17 at 6:59 AM
finance.yahoo.com logoUPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
finance.yahoo.com - October 17 at 6:59 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €90.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - October 16 at 9:44 AM
finance.yahoo.com logoBig Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It
finance.yahoo.com - October 14 at 7:33 AM
finance.yahoo.com logoSanofi and Its Peers: Analysts’ Recommendations in October
finance.yahoo.com - October 14 at 7:33 AM
finance.yahoo.com logoSpecialty Segment Drives Sanofi’s Revenue Growth in 2017
finance.yahoo.com - October 14 at 7:33 AM
benzinga.com logoA Deep Dive Into MannKind's Big Bet On Afrezza - Benzinga
www.benzinga.com - October 12 at 3:48 PM
marketwatch.com logoAppeals court rules against Amgen in patent case - MarketWatch
www.marketwatch.com - October 7 at 8:12 AM
investorplace.com logoAnalytics Keep Sanofi (SNY) Strong Buy Ranking - Investorplace.com
investorplace.com - October 7 at 8:12 AM
americanbankingnews.com logoCitigroup Inc. Analysts Give Sanofi SA (SAN) a €88.00 Price Target
www.americanbankingnews.com - October 6 at 12:28 PM
americanbankingnews.com logoMorgan Stanley Reiterates €92.00 Price Target for Sanofi SA (SAN)
www.americanbankingnews.com - October 6 at 10:28 AM
reuters.com logoUS court reverses ban on sale of Regeneron, Sanofi cholesterol drug - Reuters
www.reuters.com - October 6 at 8:32 AM
finance.yahoo.com logoSanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak
finance.yahoo.com - October 3 at 12:04 PM
finance.yahoo.com logoSanofi appoints Oelrich as executive VP at Diabetes & Cardiovascular arm
finance.yahoo.com - October 3 at 12:04 PM
finance.yahoo.com logoPregnant women still unaware of epilepsy drug risks - EMA hearing
finance.yahoo.com - September 26 at 6:37 PM
News IconU.S. FDA declines to approve J&J arthritis drug
www.businessinsider.com - September 24 at 7:40 AM
reuters.com logoFDA declines to approve J&J arthritis drug sirukumab - Reuters
www.reuters.com - September 22 at 10:58 PM
benzinga.com logoWhat's Next For L'Oreal After The Death Of Billionaire Liliane Bettencourt? - Benzinga
www.benzinga.com - September 22 at 5:56 PM
reuters.com logoUPDATE 1-US FDA declines to approve J&J arthritis drug - Reuters
www.reuters.com - September 22 at 5:56 PM
nasdaq.com logoFDA declines to approve J&J arthritis drug sirukumab - Nasdaq
www.nasdaq.com - September 22 at 5:56 PM
finance.yahoo.com logoWhy Exelixis Wouldn't Be a Warren Buffett Stock
finance.yahoo.com - September 20 at 8:40 AM
finance.yahoo.com logoAlnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
finance.yahoo.com - September 20 at 8:40 AM
finance.yahoo.com logoSanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
finance.yahoo.com - September 20 at 8:40 AM
finance.yahoo.com logoUPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment
finance.yahoo.com - September 20 at 8:40 AM
americanbankingnews.com logoJefferies Group LLC Analysts Give Sanofi SA (SAN) a €86.00 Price Target
www.americanbankingnews.com - September 18 at 6:30 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €85.00 Price Target at J P Morgan Chase & Co
www.americanbankingnews.com - September 17 at 1:32 PM
News IconUPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial
www.businessinsider.com - September 16 at 8:27 AM
finance.yahoo.com logoPatient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice
finance.yahoo.com - September 14 at 9:45 AM
reuters.com logoRegeneron, Sanofi asthma drug data fails to excite investors - Reuters
www.reuters.com - September 12 at 9:28 AM
finance.yahoo.com logoSanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL
finance.yahoo.com - September 12 at 9:28 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €83.00 Price Target at BNP Paribas
www.americanbankingnews.com - September 10 at 8:52 PM
benzinga.com logoWhat Pharmaceuticals Spend On Lobbying To Influence Trump - Benzinga
www.benzinga.com - September 10 at 7:15 AM
cnn.com logoSanofi stops work on Zika vaccine while others forge forward
www.cnn.com - September 8 at 7:59 AM
americanbankingnews.com logoSanofi SA (SAN) Earns "Neutral" Rating from J P Morgan Chase & Co
www.americanbankingnews.com - September 8 at 6:22 AM
reuters.com logoQuest to offer cholesterol testing without fasting requirement - Reuters
www.reuters.com - September 7 at 8:39 AM
wsj.com logoSanofi Stops Work on Two Zika Vaccines - Wall Street Journal (subscription)
www.wsj.com - September 7 at 8:39 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €90.00 Price Target by Kepler Capital Markets Analysts
www.americanbankingnews.com - September 7 at 7:18 AM
finance.yahoo.com logoWhy Is Regeneron (REGN) Up 7.9% Since the Last Earnings Report?
finance.yahoo.com - September 5 at 7:53 AM
benzinga.com logoThe Pullback In Sanofi Is A Buying Opportunity, Says Argus - Benzinga
www.benzinga.com - September 2 at 8:18 AM
finance.yahoo.com logoThe Pullback In Sanofi Is A Buying Opportunity, Says Argus
finance.yahoo.com - September 2 at 8:18 AM
nasdaq.com logoSanofi Closes Acquisition Of Influenza Vaccine Developer Protein Sciences - Nasdaq
www.nasdaq.com - August 29 at 7:31 AM
rttnews.com logoSanofi Closes Acquisition Of Influenza Vaccine Developer Protein Sciences
www.rttnews.com - August 28 at 6:19 AM
seekingalpha.com logoSanofi Takes A Multipronged Approach To Maintaining Its Dividend Performance
seekingalpha.com - August 25 at 11:11 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €87.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 24 at 3:22 PM

Social

Social activity is not available for this stock.
This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.